The global Network Point-of-Care Glucose Testing Market was valued at around USD 1.5 billion in 2021.
With a projected CAGR of 4.8% for the next ten years, the market is likely to reach a valuation of nearly USD 2.5 billion by the end of 2032. The Global absolute dollar opportunity growth in network point-of-care glucose testing is projected to be at USD 923.3 million by 2032.
| Attributes | Details |
|---|---|
| Network Point-of-Care Glucose Testing Market Size (2021) | USD 1.5 billion |
| Network Point-of-Care Glucose Testing Market Size (2022) | USD 1.6 billion |
| Projected Market Value (2032) | USD 2.5 billion |
| Global Market Growth Rate (2022 to 2032) | 4.8% CAGR |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Danaher.; Abbott; Nipro; PlatInium Equity Advisors, LLC; Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics |
Explore FMI!
Book a free demo
Network point-of-care glucose testing is a growing testing method that does not require testing in the laboratory but is instead performed near or at the site of the patient to monitor the glucose levels. This ensures minimal risk of infection and provides information within a few seconds.
Future Market Insights reveals that revenue from Accu-Chek Inform II dominated the segment of product type. Revenue from Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. It is projected to achieve a growth rate of 4.9% during the forecasted period of 2022 to 2032.
On the other hand, North America dominated the market for network-point-of-care glucose testing. It achieved a growth rate of 4.8% from 2017 to 2021 and is projected to witness revenue growth of 4.9% CAGR over the forecasted period.
Network Point-of-care glucose testing is significantly gaining traction for the diagnosis of diabetes as well as for analyzing patients’ health conditions. It has come as an efficient tool for preventing delays in treatment and providing results in less time. Moreover, the demand for remote patient monitoring systems and the need for data-based patient results are driving the market for network point-of-glucose testing.
As the number of diabetes patients is surging, there is an increasing demand to incorporate the patient data and perform proper management of the data to derive insightful information and develop an advanced method for data transfer techniques.
The growing incidence of diabetes necessitates glucose testing among individuals. According to WHO data, 422 million people globally are suffering from diabetes, the majority of whom are living in underdeveloped countries.
Therefore, the treatment of glucose testing becomes vital for these nations as they remain undiagnosed and are at risk of developing diseases associated with diabetes such as blindness, kidney failure, stroke, and heart attack.
Based on a WHO report in 2019, diabetes contributed to the ninth leading cause of death with an estimation of 1.5 million deaths. According to Diabetes Federation data published in 2021, almost 1 in 2 diabetes patients were undiagnosed, and in Asia-Pacific, the proportion was estimated to be 55%, largely contributed by India, China, and Indonesia.
Therefore, it becomes essential to expand the coverage of network point-of-care glucose testing methods in low and middle-income countries as well as developed countries.
North America is the largest user of network point-of-care testing methods. Revenue through Network point-of-care glucose testing grew at a CAGR of 4.8% from 2017 to 2021. North America is expected to dominate the market with a 4.9% CAGR from 2022 to 2032. Prominent key players such as Abbott, Nova Medical, and prodigy Diabetes Care, LLC are aiding the regional market growth. Moreover, several initiatives by the government and not-for-profit organizations to increase awareness about the adoption of advanced glucose meters are driving growth in North America.
The network point-of-care glucose testing market in the USA was valued at USD 735 million by 2032. Revenue through the market grew at 4.6% CAGR from 2017 to 2021. The projected growth rate in the network point-of-care glucose testing market is 4.9% over the forecasted period. According to the data from American Diabetes Association, almost 37.3 million Americans, or 11.3% of the population had diabetes in 2019.
Out of which 8.5 million were undiagnosed and 244,000 children and adolescents in the USA were suffering from diabetes. This necessitates the need for conducting point-of-care glucose testing among individuals and ensuring early recovery from chronic disease.
Key companies like Abbott had maintained their presence in the USA market by providing FreeStyl e Libre 2 integrated continuous glucose monitoring system which is used by the most number of Americans to track health statistics in a mobile app. The absolute dollar opportunity growth in the network point-of-care glucose testing market in the USA is USD 276.2 million by 2032.
The network point-of-care glucose testing market in the United Kingdom is projected to reach a valuation of USD 119 million by 2032. Growing at a CAGR of 5.8%, the market is expected to register an absolute dollar opportunity of USD 50.6 million from 2022 to 2032.
The market in Japan is expected to gross an absolute dollar opportunity of USD 36 million during the forecast period. Growing at a CAGR of 4.5%, the market is likely to reach a valuation of USD 101 million by 2032.
In South Korea, the market is projected to reach a valuation of USD 59 million by 2032. Growing at a CAGR of 4.9%, the market from 2022 to 2032 is expected to gross an absolute dollar opportunity of USD 23 million.
Accu-Chek Inform II is widely used as a point-of-care glucose testing monitor. Revenue through Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. The anticipated growth rate of Accu-Chek Inform II is 4.9% during the forecasted period of 2022 to 2032.
The rise in the use of Accu-Chek Inform II is attributed to its automatic real-time wireless features which enable proper transmission of patient data between the medical staff and the laboratories. The system also offers unique features such as unique identification of patients to avoid inaccuracy.
Due to the prevalence of diabetes in Asia, the network point-of-care glucose testing market is expected to witness growth in the forecasted period. Almost 90 million adults are suffering from diabetes in the IDF South-East Asia region and is estimated to witness a spike in diabetes patients to 152 million by 2045. Countries in the Asia-Pacific have made efforts to employ point-of-care glucose testing methods to reduce the occurrence of diabetes.
For instance, in China, the government incentivized hospitals to employ diabetes management systems. Hospitals in Tianjin have administered blood glucose information systems to improvise blood glucose monitoring, treatment, and management.
Companies involved in network point-of-care glucose testing are solely aiming at increasing diabetes awareness and producing advanced point-of-care glucose testing devices. The key companies operating in the network point-of-care glucose testing market include F.
Hoffmann-La Roche Ltd. Danaher, Abbott, Nipro, Platinum Equity Advisors, LLC (Lifescan, Inc.), Nova Biomedical, ACON Laboratories, Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics and others.
Some of the recent developments by key providers of Network Point-of-Care Glucose Testing are as follows:
Similarly, recent developments related to companies operating in the network point-of-care glucose testing market have been tracked by the team at Future Market Insights, which is available in the full report.
The global Network Point-of-Care Glucose testing market was valued at USD 1.5 billion in 2021 and USD 1.6 billion in 2022.
The Network Point-Of-Care glucose testing industry is set to witness a high growth rate of 4.8% over the forecast period and is valued at USD 2.5 by 2032.
Accu-Chek Inform II maintained its largest share and grew at a CAGR of 4.5% from 2017 to 2021.
F. Hoffmann-La Roche Ltd., Danaher, Abbott, Nipro, Platinum Equity Advisors, LLC (Lifescan, Inc.), Nova Biomedical, ACON Laboratories, Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics are the key operators in Network Point-of-Care Glucose Testing market.
North America dominates the market for network point-of-care glucose testing with 4.8% CAGR from 2017 to 2021. The anticipated growth rate of North America is 4.9% during the forecasted period.
The USA, United Kingdom, China, Japan, and South Korea are expected to drive the highest demand for the Network Point-of-Care Glucose testing market.
Revenue through the Network Point-of-Care Glucose testing market in North America grew by 4.8% from 2017 to 2021. The projected growth rate in North American in-network point-of-care glucose testing is 4.9% over the forecasted period.
The Network Point-of-Care Glucose testing market in the USA is valued at USD 735 million in 2032 and is expected to achieve a growth rate of 4.9% during the forecasted year.
Acrylic Teeth Market Trends and Assessment for 2025 to 2035
Bariatric Beds Market Analysis and Forecast for 2025 to 2035
Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market Growth and Analysis: 2025 to 2035
Uterine Manipulation Devices Market - Growth & Demand 2025 to 2035
Retinal Vein Occlusion Treatment Market - Outlook 2025 to 2035
Klinefelter Syndrome Therapeutics Market - Growth & Demand 2025 to 2035
Network Point-of-Care Glucose Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
